Eye Injections of Bevacizumab for Lowering Risk of Scar Tissue in the Retina and Repeated Retinal Detachment.

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
Wills Eye
Study ID
NCT01860586
Status
Completed

Conditions

  • Retinal Detachment
  • Vitreoretinopathy Proliferative

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    Bevacizumab (1.25mg/0.05mL) will be injected into the study eye, at the end of the surgical repair of the retinal detachment and at Month 1, 2 and 3.

Study Details

The purpose of this study is to examine the effects of a drug called bevacizumab (Avastin) on the rates of recurrent retinal detachment and scar tissue formation.

Key Dates

First listed
May 22, 2013
Start date
Jun 30, 2013
Status verified
Mar 2017
Primary completion
Nov 30, 2014
Completion
Nov 30, 2014

Study Design

Enrollment
20 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Bevacizumab
    Bevacizumab will be injected into the study eye at end of retinal detachment (rd) surgery and monthly for the following 3 months (total of 4 intravitreal bevacizumab injections)

Primary Outcome Measure

The Effect of Intravitreal Bevacizumab Injections on Rate of Recurrent Retinal Detachment (Increase or Decrease) [ Time Frame: up to 6 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Mid Atlantic Retina- Wills Eye InstitutePhiladelphiaPennsylvania19107-

Find similar trials in Philadelphia, PA

By research site
Mid Atlantic Retina- Wills Eye Institute· Philadelphia, PA

Related Studies